

Neurology Medical Group of Diablo Valley  
108 La Casa Via  
Suite 105  
Walnut Creek, CA 94598  
Phone: 925-939-9400, Fax: 925-939-1819

# Raymond Martin Stephens , MD

## Certifications

American Board of Electrodiagnostic Medicine - EMG & Neuromuscular Disease	1986
American Board of Psychiatry and Neurology - Neurology	1984
American Board of Qualifications in Electroencephalography - EEG	1982

## Licensure

Primary MD - G40939, California

## Academic Degrees

MD - University of California San Diego, San Diego, CA	1978
AB - Physiology, University of California Berkeley, Berkeley, CA	1974
Physics Courses - University of Santa Clara, Santa Clara, CA	1972

## Residencies and Internships

Chief Resident - Neurology, University of California San Diego, San Diego, CA	1981 - 1982
Resident - Neurology, University of California San Diego, San Diego, CA	1979 - 1982
Internship - Internal Medicine, University of Michigan, Ann Arbor, MI	1978 - 1979

## Professional Societies

American Heart Association/American Stroke Association  
National Stroke Association  
Bay Area Stroke Society  
American Association of Neuromuscular and Electrodiagnostic Medicine  
American Academy of Neurology  
California Medical Association

## Experience

Private Practice of Neurology - Neurology Medical Group of Diablo Valley, Walnut Creek, CA	1982 - present
--	----------------

## Appointments

Director Stroke Program John Muir Health System	2004 - present
---	----------------

Assistant Clinical Professor of Neurology, University of California Davis, Davis, CA 1982 - 1985  
 Assistant Clinical Professor - Neurology (Pediatric Neurology), University of California San Francisco, San Francisco, CA 1982 - 1984

**Awards**

Bay Area Consumer's Checkbook- Winter 1999  
 Listed in Best Bay Area Medical Specialists  
 San Francisco Magazine- January, 2001  
 Listed in 500 Best MD's in Bay Area  
 Student Teaching Award in Neurology 1982  
 Highest Honors - University of California Berkeley, Berkeley, CA 1974  
 Outstanding Student Award, Physiology - University of California Berkeley, Berkeley, CA 1974  
 Phi Beta Kappa - University of California Berkeley, Berkeley, CA 1974

**Current Hospital Affiliations**

John Muir Medical Center - Walnut Creek, CA Campus (JCAHO certified primary stroke center)  
 John Muir Medical Center - Concord, CA Campus (JCAHO certified primary stroke center)

**Research Activities**

*PRINCIPAL INVESTIGATOR*

A double-blind, active and placebo-controlled study of Aggrenox® vs. Clopidogrel + aspirin, with and without Micardis® (PROFESS) 2003 – present  
 A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess The Efficacy and Safety of Intravenous NXY-059 In Acute Ischemic Stroke (SAINT II) 2003 – present  
 A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess The Safety of Intravenous NXY-059 In Acute Cerebral Hemorrhage (CHANT) 2003 – 2005  
 A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled, Fixed Dose Response Study Comparing the Efficacy and Safety of Sumanriole versus Placebo in Patients with Early Parkinson's Disease 2003 - 2005  
 A Multicenter, Prospective and Retrospective, Long-Term Observational Study of AVONEX ® and Rebif® to Determine the Efficacy, Tolerability, and Safety in Subjects with Relapsing Multiple Sclerosis (MS) (PROOF) 2003 – 2004  
 Phase I, A Single Rising Dose Study of FK506 Lipid Complex (LCG) in Patients With Recent Ischemic Stroke 2002 – 2003  
 A Multi-Center, open-label, randomized, 4-way crossover trial of the safety and 2002

Efficacy of Tizanidine Hydrochloride Capsules versus Zanaflex® (Tizanidine Hydrochloride) Tablets taken under fed and fasted conditions in patients with Moderate to severe Spasticity

A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole versus Placebo or Ropinerole in Patients with Early Parkinson's Disease 2002 – 2003

Open-Label, Long-Term, Flexible Dose Study of Safety, Tolerability and Therapeutic Response in Patients with Parkinson's Disease: PNU-95666E 2002 – 2004

Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack or Ischemic Stroke: A Randomized, Double-Blind Study, With 18 Months Follow-up. (MATCH) 2001 – 2004

A Randomized, Placebo-Controlled, Three Treatment Arm Study to Determine the Safety and Efficacy of Argatroban Injection in Patients with Acute Ischemic Stroke 2001 – 2002

12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Preliminary Study to Determine the Efficacy and Safety of Donepezil Hydrochloride (E2020) in Patients With Persistent Mild to Moderate Memory Impairments Resulting From a Single Closed Head Injury 2001 – 2002

Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Effects of YM872 on Lesion Volume as Measured by Diffusion, Perfusion and FLAIR Magnetic Resonance Imaging in Patients with Acute Ischemic Stroke (ARTIST MRI) 2001 - 2003

Multicenter, Stratified, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Neurologic Function and Disability in Patients with Acute Ischemic Stroke Given Tissue Plasminogen Activator Plus YM872 or Tissue Plasminogen Activator Plus Placebo (ARTIST+) 2001 - 2003

Phase III Multicenter, Double-Blind, Parallel-Group Placebo Controlled Study of the Effect of Riluzole 50 mg BID or 100 mg BID on the Progression of Parkinson's Disease in Patients Treated with L-Dopa or Dopamine Agonist 2001

Acute Ischemic Stroke Protocol 161-106, Phase II 2000

"Blockade of the GP IIB/IIIa Receptor to Avoid Vascular Occlusion (BRAVO), Phase III." 1999 – 2001

A Phase III, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Hu23F2G (LeukArrest™) in Patients with Acute Ischemic Stroke. 1999 – 2000

"A 4-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Three Dose Levels of Compound When Administered Daily for 28 Days by Subcutaneous Injection on Diabetic Painful Neuropathy in Patients with Type 1 or Type 2 Diabetes Mellitus." 1998 – 1999

The Acute Stroke Study in Ischemic Stroke (Class-I): "A Double-Blind, Parallel-Group, Multinational, Multicenter Study of the Efficacy and Safety of IV Compound Compared to Placebo in Patients with Acute Ischemic Stroke." 1997 – 2000

The Acute Stroke Study in Acute Intracerebral Hemorrhage (Class-H): A Double-Blind, Parallel-Group, Multinational, Multicenter Study of Safety of IV Compound Compared to Placebo in Patients with Acute Intracerebral Hemorrhage." 1997 – 1999

The Acute Stroke Study in t-PA Treated Ischemic Stroke (Class-T): "A Double-Blind, Parallel-Group, Multinational, Multicenter Study of the Safety of IV Compound Compared to Placebo in Patients Treated with t-PA (Tissue Plasminogen Activator) for Acute Ischemic Stroke."	1997 – 1999
"Lubeluzole Int-13 Acute Stroke Study."	1997
"t-PA Acute Stroke less than 3 hr Study, Phase IV."	1997
"t-PA 3 to 5 Hour Acute Stroke Study."	1996
"Open Label, Multicenter Trial of the Safety and Efficacy of Compound in the Treatment of Alzheimer's Disease."	1996
"Enlimomab Acute Stroke Study, Phase III."	1995 – 1996
"DHE 454 Migraine Study, Phase III."	1995
"Structural analysis of hair roots for assessment of malnutrition in large populations. Assistant World Health Organization Consultant to Guatemala, with application of above technique. (University of California, Berkeley, with Dr. Robert Bradfield)	1975
"Structural analysis of chloroplast membranes using electron spin resonance technique." (University of California Physiology Degree Thesis with Dr. Lester packer)	1973 – 1974

*SUBINVESTIGATOR*

A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron® 250µg Subcutaneously Every Other Day with Avonex® 30µg Intramuscularly Once per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated with Avonex® (ABOVE)	2003 – 2005
A Prospective, 26-Week, Open-label, Multi-center Study Evaluating the Efficacy And Safety of Exelon (rivastigmine tartrate) 3 – 12 mg/day in Patients with Mild To Moderate Alzheimer's Disease Who Are Responding Poorly to Aricept® (donepezil) Treatment (EXCEL)	2003 – 2004
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)	2003 – 2004
E2020-A001-319 A 24-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy, Safety and Tolerability of Donepezil Hydrochloride (E2020) in Patients with Dementia Associated with Cerebrovascular Disease	2003– 2004
Medical Index for Neuromuscular Data (MIND) Registry	2002 – 2005
Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy of Latranal Compared to Doxepin Cream and Placebo in Patients with Chronic Low Back Pain	2001
Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H 376/95 Compared with Dose-Adjusted Warfarin (Coumadin©) in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (SPORTIF V)	2000 – 2003

Phase II, 12 Week, Randomized, Double-Blind, Placebo Controlled, Multicenter Study Evaluating the Safety and Efficacy of Three Fixed Doses of Oral CP-457,920 (30 mg QD, 60 mg BID and 120 mg BID) and Donepezil in Outpatients with Alzheimer's Disease	2000 – 2002
Lamictal® in Combination with Newer and Older Antiepileptic Drugs and as Monotherapy: A Practical Clinical Assessment of Tolerability and Clinical Effectiveness (The TARGET Study: <u>T</u> rial to <u>A</u> ssess and <u>R</u> efine <u>G</u> lobal <u>E</u> pilepsy <u>T</u> reatment)"	1999 – 2000
"The Safety and Efficacy of MK-0966 in Slowing the Progression of the Symptoms of Alzheimer's Disease"	1999 – 2000
"A 24-Month, Double-Blind, Randomized, Placebo-Controlled, Fixed-Dose, Parallel-Group, Multicenter Study of Zenerstat in the Treatment of Diabetic Neuropathy"	1999 – 2000
Pregabalin BID, Open-Label, Add-On Trial: "An Open-Label, Multicenter, Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures."	1998 – 2005
Pregabalin BID Add-On Trial: "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study in Patients with Partial Seizures."	1998 – 1999
"Topamax Monotherapy Comparison Trial to Standard Monotherapy in the Treatment of Newly Diagnosed Epilepsy."	1998 – 2000
An Open-Label Study to Evaluate the Safety and Efficacy of 1.5 mg b.i.d. (3 mg/day) through 6 mg b.i.d.(12 mg/day) of Exelon in Patients with Mild to Severe Probable Alzheimer's Disease in the Community Setting."	1997
"NGF in Diabetic Polyneuropathy, Phase III."	1998
"Design of cryogenic magnetic shield device for lunar magnetic field experiments." (Ames Research Center: Apollo 12 Lunar Magnetometer Project)	1971